Navigation Links
How do anticancer drugs work?
Date:5/3/2013

RIVERSIDE, Calif. Anticancer drugs save lives and/or improve the quality of life for many cancer patients. Many anti-cancer drugs work by killing tumor cells after inducing damage to DNA.

The public has an opportunity to learn about the mechanisms of action of some commonly used anticancer drugs and how laboratory research may lead to novel targets and new strategies for cancer treatment.

Yinsheng Wang, a professor of chemistry at the University of California, Riverside, will give a free lecture on May 16 on campus to discuss those drugs that induce damage to DNA, as well as those biomolecules that allow for selective targeting of tumor cells. He will also discuss the implications of personalized medicine in cancer treatment.

Wang's hour-long talk is titled "Curing cancer: How do anticancer drugs work?" It will begin at 5:30 p.m. in Rooms C, D and E, University Extension Center (UNEX). Seating is open. Parking at UNEX is free for lecture attendees.

The lecture is the third in the annual Science Lecture Series hosted by the College of Natural and Agricultural Sciences (CNAS). This year the theme is "The Science of Disease." The series aims to boost the public's awareness and understanding of science and of how scientists work.

"Anti-cancer drugs induce their cytotoxic effects via different molecular targets," Wang said. "Patients' genetic make-up can have a significant effect on the clinical efficacies of anti-tumor drugs. Innovative technologies may lead to the discovery of new molecular targets that can be used for more effective treatment of cancer while minimizing side effects."

Wang is the director of the Environmental Toxicology Graduate Program at UC Riverside. He received his bachelor's degree from Shandong University and master's degree from the Chinese Academy of Sciences. He joined the UCR faculty in 2001, after earning his doctoral degree from Washington University in St. Louis.

He is the recipient of the 2013 Biemann Medal and a 2005 Research Award from the American Society for Mass Spectrometry, as well as the inaugural Chemical Research in Toxicology Young Investigator Award from the American Chemical Society in 2012. He was named a Fellow of the American Association for the Advancement of Science in 2012.

Research in the Wang group is concentrated in two broad areas. The first is DNA damage and repair. His lab uses a variety of chemical and biological tools to understand, at the molecular level, how various kinds of damage to DNA are repaired, and how they affect the flow of genetic information during DNA replication and transcription. His work has brought scientists' understanding of the biological consequences of DNA damage to a new level.

His lab's second research area is proteomics, the study of the functions, structures, and interactions of proteins. His work in this area has led to the discovery of novel mechanisms of action of some anti-tumor drugs and environmental toxicants. In particular, he seeks to understand alterations in the expression of proteins in cells that are treated with anticancer drugs and other agents.

Wang's lecture will be introduced by Aurora Johnson, a physical science teacher in the Moreno Valley Unified School District with 11 years of teaching experience. Previously, she worked in the Riverside and Palm Springs Unified School Districts. She was educated at Riverside City College, Grand Canyon University, and UCR.


'/>"/>

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside
Source:Eurekalert

Related biology news :

1. 11th International Congress on Targeted Anticancer Therapies
2. Harnessing anticancer drugs for the future fight against influenza
3. High levels of TRAIL protein in breast milk might contribute to anticancer activity
4. Mapping of cancer cell fuel pumps paves the way for new drugs
5. Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes
6. Cholesterol rafts deliver drugs inside cancer cells
7. Findings to help in design of drugs against virus causing childhood illnesses
8. KU Leuven lab coordinates €9m effort to find new deep-sea drugs
9. Mood-modifying drugs for humans also alter fish behavior
10. Study finds potential to match tumors with known cancer drugs
11. £6.5M in funding to help manufacture the drugs of the future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
Breaking Biology Technology: